What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News XORTX surges after $3M Vectus Biosystems deal adds promising anti-fibrotic kidney drug to pipeline Find out how XORTX’s $3 million Vectus Biosystems acquisition could reshape the renal fibrosis market and accelerate its transformation into a leading kidney disease innovator. bySoujanya RaviOctober 17, 2025